Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RVTY 
Revvity Inc. (RVTY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: RVTY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $116.81
1 Year Target Price $116.81
| 10 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.98% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.62B USD | Price to earnings Ratio 36.03 | 1Y Target Price 116.81 |
Price to earnings Ratio 36.03 | 1Y Target Price 116.81 | ||
Volume (30-day avg) 19 | Beta 0.95 | 52 Weeks Range 81.36 - 129.23 | Updated Date 09/14/2025 |
52 Weeks Range 81.36 - 129.23 | Updated Date 09/14/2025 | ||
Dividends yield (FY) 0.33% | Basic EPS (TTM) 2.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.19% | Operating Margin (TTM) 14.31% |
Management Effectiveness
Return on Assets (TTM) 2.05% | Return on Equity (TTM) 3.61% |
Valuation
Trailing PE 36.03 | Forward PE 15.15 | Enterprise Value 12001944704 | Price to Sales(TTM) 3.44 |
Enterprise Value 12001944704 | Price to Sales(TTM) 3.44 | ||
Enterprise Value to Revenue 4.29 | Enterprise Value to EBITDA 14.6 | Shares Outstanding 116073000 | Shares Floating 108560363 |
Shares Outstanding 116073000 | Shares Floating 108560363 | ||
Percent Insiders 0.34 | Percent Institutions 100.51 |
Upturn AI SWOT
Revvity Inc.
Company Overview
History and Background
Revvity Inc. (formerly PerkinElmer) was founded in 1931. Initially focused on optics, it evolved into a global leader in life sciences, diagnostics, and applied solutions, achieving significant milestones through innovation and strategic acquisitions.
Core Business Areas
- Life Sciences: Provides research tools, reagents, and services for drug discovery, genomics, and proteomics.
- Diagnostics: Offers diagnostic solutions for prenatal screening, newborn screening, and infectious disease testing.
- Applied Solutions: Delivers analytical instruments and services for environmental, food, and industrial testing.
Leadership and Structure
Prahlad Singh serves as the Chief Executive Officer. The organizational structure includes distinct business units responsible for Life Sciences, Diagnostics, and Applied Solutions.
Top Products and Market Share
Key Offerings
- DELFIA Assays: Time-resolved fluorescence immunoassays used in drug discovery and clinical diagnostics. Competitors include Roche and Thermo Fisher Scientific. Market share varies by specific assay and application.
- u09a8u09acu099cu09beu09a4u0995u09c7u09b0 u09b8u09cdu0995u09cdu09b0u09bfu09a8u09bfu0982: Solutions and instruments for newborn screening, detecting genetic and metabolic disorders. Competitors include Roche and Agilent. Revvity has a strong global presence in this market.
- AlphaLISA Assays: Homogeneous bead-based assay technology for drug discovery. Competitors include Cisbio Bioassays and Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The life sciences and diagnostics industries are experiencing growth driven by increasing healthcare spending, technological advancements, and aging populations.
Positioning
Revvity Inc. is positioned as a leading provider of innovative solutions in life sciences and diagnostics, with a competitive advantage in its extensive product portfolio and global reach.
Total Addressable Market (TAM)
The total addressable market for life sciences and diagnostics is estimated to be in the hundreds of billions of dollars. Revvity Inc. holds a significant portion but has room for growth with respect to this TAM.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Global presence
- Strong brand recognition
- Innovative technologies
- Experienced management team
Weaknesses
- Integration challenges from acquisitions
- Exposure to economic cycles
- Complexity of operations
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests
- Strategic acquisitions
- Increasing demand for personalized medicine
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ROSY
- A
- WAT
Competitive Landscape
Revvity Inc. competes with larger and more diversified companies. It differentiates itself through specialized solutions and customer focus.
Major Acquisitions
BioLegend
- Year: 2021
- Acquisition Price (USD millions): 2800
- Strategic Rationale: Expanded Revvity's life sciences portfolio and strengthened its position in the biopharmaceutical market.
Growth Trajectory and Initiatives
Historical Growth: Revvity Inc. has grown through organic growth and strategic acquisitions.
Future Projections: Future growth projections data to be updated as available. Analyst estimates must be obtained directly from financial data providers.
Recent Initiatives: Recent strategic initiatives data to be updated as available. Company press releases and SEC filings must be consulted.
Summary
Revvity Inc. is a global leader in life sciences and diagnostics, with a diverse product portfolio and strong brand recognition. While its global presence and innovative technologies are strengths, it faces integration challenges and intense competition. Revvity must capitalize on emerging markets and new diagnostic tests while mitigating threats like regulatory changes and economic downturns to sustain growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Financial Data Providers (e.g., Bloomberg, Refinitiv)
- Industry Reports
- Company Press Releases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Always consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revvity Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1983-04-06 | CEO, President & Director Dr. Prahlad R. Singh Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.revvity.com |
Full time employees 11000 | Website https://www.revvity.com | ||
Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.